Stocks to Buy Today - Stock Message Board, Discussion Forum, Blog
Threshold Pharmaceuticals, Inc. (THLD) is the best stock in 2012 ytd. Threshold Pharmaceuticals, Inc. (THLD) stock is currently trading at $6.46 and is higher by 430% in 2012.
Threshold Pharmaceuticals, Inc. (THLD) has a cancer drug TH-302 for pancreatic cancer that will begin phase 3 trials later this year. THLD recently partnered with Merck KGaA and has been receiving milestone payments as goals are met.
THLD is a highly manipulated stock. After hitting $6.65, the stock sold off all the way down to the $4.30's. The company announced a slight earnings beat due to low expenses and the stock raced to a new 52 week high on Friday, $6.75.
TH-302 has been shown in phase 2 trials to prolong the lives in pancreatic cancer patients as much as 2 months when combined with another drug, gemcitabine.
I have been all over this stock during the last four weeks and knew that once it broke back above $4.96, the stock would rally. At some point, THLD will have another gut wrenching sell-off leaving longs wondering what they are holding. But for now, the bulls seem to be in control again.
The company plans to released key phase 2b trial data at the AACR conference
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that a Late-Breaking clinical abstract has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held on March 31st - April 4th 2012, in Chicago, IL. The presentation will report the detailed results from the randomized Phase 2b trial of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer.
The abstract's title and presentation details are provided below. Per AACR policy, all data are embargoed until the time of the beginning of the presentation.
Hey Tim, How's florida??? Enjoying the summer sun?
Bought some THLD back today.....$6.90 is resistance and if the stock can break back above $7, it will probably be off to the races again.
Are still holding THLD ? I sold more than 50% of my position. Where do you see a resistance right now ? $7.00
I actually sold on one of the big rallies last week. Resistance is located around $7.50. Support is around $6.70. The stock looks strong buy selling on the way up is a good idea.
Thanks Tim, I think THLD could run a bit more I think I will kept it with a tight stop
You could maybe use today's low of $7.10 as a good stop out point. If the low increases on Monday, move it up. I was willing to take the risk below $6 recently but now it cam go either way at this point.
Yeah, I think its a good strategy to do it. At least I still have a gain (almost $1 per share)
Threshold Pharmaceuticals: TH-302 Phase IIb Clinical Results In First-Line Pancreatic Cancer
Stock Valuation With total diluted shares of 53.6M and a stock price of $6.86, Threshold has a market cap of 356.7MM and an EV of approximately 316.4MM. Commercial sales of TH-302 may start as early as in 2014 if TH-302 is approved for the pancreatic cancer indication based on Phase II data. The NDA may otherwise be filed for FDA approval in the pancreatic cancer indication in 2016 or 2017, and in the soft tissue sarcoma indication in 2015, after Phase III trials. Under the current deal structure, Threshold is expected to share profits from TH-302 sales in the U.S., where the drug could reach blockbuster status.
To estimate the intrinsic EV of Threshold, we looked at four biotech companies currently treading in NASDAQ: Alexion (ALXN), Vertex (VRTX), Amylin (AMLN) and BioMarin (BMRN), among which the median EV/Sales multiple is 9.6. The four companies have annual sales ranging from 441.4MM to 950.9MM. With an EV/S multiple of 9.6, we estimated that the EV for Threshold should be ~$4.8B in 2020. With a beta of 2.38, the required rate of return (IRR) for THLD investors is roughly 23%. Using the IRR to discount the estimated EV in 2020 back to 2012, we estimated that the intrinsic EV of Threshold should be approximately $733MM, or 2.3x higher than its current level, which equates to a~$15 share price. Of course, the estimation heavily depends on the outcome of the Phase IIb OS data. In summary, we remain cautiously optimistic on Threshold stock outlook and believe that the stock should rise significantly should the company release positive OS data.
Analyst Cowen out this morning saying Threshold Pharmaceuticals, Inc. (THLD) is undervalued - outperform rating
With this news, could be a good trade today.
What do you think ?
The chart looks is hitting resistance
When THLD starts breaking out again, it will probably go up above $10 is my guess....there has been a long basing pattern between $6-$7